Rekovelle (follitropin delta) is recommended by EMA's CHMP for controlled ovarian stimulation-Ferring Pharmaceuticals
The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Rekovelle (follitropin delta), from Ferring Pharmaceuticals, intended for controlled ovarian stimulation in women undergoing assisted reproductive technologies (ART).
Rekovelle will be available as a solution for injection (12 ?g/0.36 ml, 36 ?g/1.08 ml and 72 ?g/2.16 ml). The benefits with Rekovelle are its ability to stimulate the development of multiple mature follicles in the ovaries. The most common side effects are headache, pelvic discomfort, ovarian hyperstimulation syndrome (OHSS), pelvic or adnexal pain, nausea and fatigue.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins